Historical Valuation
BioRestorative Therapies Inc (BRTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.48 is considered Undervalued compared with the five-year average of -1.82. The fair price of BioRestorative Therapies Inc (BRTX) is between 1.46 to 1.77 according to relative valuation methord. Compared to the current price of 1.20 USD , BioRestorative Therapies Inc is Undervalued By 18.05%.
Relative Value
Fair Zone
1.46-1.77
Current Price：1.20
18.05%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
BioRestorative Therapies Inc (BRTX) has a current Price-to-Book (P/B) ratio of 4.44. Compared to its 3-year average P/B ratio of 1.51 , the current P/B ratio is approximately 193.38% higher. Relative to its 5-year average P/B ratio of -1.02, the current P/B ratio is about -537.24% higher. BioRestorative Therapies Inc (BRTX) has a Forward Free Cash Flow (FCF) yield of approximately -99.46%. Compared to its 3-year average FCF yield of -67.95%, the current FCF yield is approximately 46.38% lower. Relative to its 5-year average FCF yield of -55.39% , the current FCF yield is about 79.56% lower.
P/B
Median3y
1.51
Median5y
-1.02
FCF Yield
Median3y
-67.95
Median5y
-55.39
Competitors Valuation Multiple
AI Analysis for BRTX
The average P/S ratio for BRTX competitors is 11.23, providing a benchmark for relative valuation. BioRestorative Therapies Inc Corp (BRTX.O) exhibits a P/S ratio of 5.48, which is -51.17% above the industry average. Given its robust revenue growth of -94.95%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BRTX
1Y
3Y
5Y
Market capitalization of BRTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BRTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BRTX currently overvalued or undervalued?
BioRestorative Therapies Inc (BRTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.48 is considered Undervalued compared with the five-year average of -1.82. The fair price of BioRestorative Therapies Inc (BRTX) is between 1.46 to 1.77 according to relative valuation methord. Compared to the current price of 1.20 USD , BioRestorative Therapies Inc is Undervalued By 18.05% .
What is BioRestorative Therapies Inc (BRTX) fair value?
BRTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BioRestorative Therapies Inc (BRTX) is between 1.46 to 1.77 according to relative valuation methord.
How does BRTX's valuation metrics compare to the industry average?
The average P/S ratio for BRTX's competitors is 11.23, providing a benchmark for relative valuation. BioRestorative Therapies Inc Corp (BRTX) exhibits a P/S ratio of 5.48, which is -51.17% above the industry average. Given its robust revenue growth of -94.95%, this premium appears unsustainable.
What is the current P/B ratio for BioRestorative Therapies Inc (BRTX) as of Jan 10 2026?
As of Jan 10 2026, BioRestorative Therapies Inc (BRTX) has a P/B ratio of 4.44. This indicates that the market values BRTX at 4.44 times its book value.
What is the current FCF Yield for BioRestorative Therapies Inc (BRTX) as of Jan 10 2026?
As of Jan 10 2026, BioRestorative Therapies Inc (BRTX) has a FCF Yield of -99.46%. This means that for every dollar of BioRestorative Therapies Inc’s market capitalization, the company generates -99.46 cents in free cash flow.
What is the current Forward P/E ratio for BioRestorative Therapies Inc (BRTX) as of Jan 10 2026?
As of Jan 10 2026, BioRestorative Therapies Inc (BRTX) has a Forward P/E ratio of -1.11. This means the market is willing to pay $-1.11 for every dollar of BioRestorative Therapies Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BioRestorative Therapies Inc (BRTX) as of Jan 10 2026?
As of Jan 10 2026, BioRestorative Therapies Inc (BRTX) has a Forward P/S ratio of 5.48. This means the market is valuing BRTX at $5.48 for every dollar of expected revenue over the next 12 months.